Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Comparative analysis of HIV-1 recombinant envelope glycoproteins from different culture systems

  • 106 Accesses

  • 3 Citations


The productivity of stable Chinese hamster ovary cell lines secreting HIV-1 monomeric (IIIB gp120) and oligomeric (UG21 gp140) recombinant envelope glycoproteins was compared in serum-containing (S+), serum-free (S−) and protein-free (P−) culture media. UG21 gp140 expression was greatest in S+ medium, while IIIBgp120 production was lower than gp140 in all three media but highest in S−. UG21 gp140 production was highest in standard 850-cm2 roller bottle cultures in S+ media, peaking after 14 days of incubation, while expression levels in the three media were 0.5 (S+), 0.4 (S−) and 0.2 (P−) mg/l, from which 90, 80 and 12% of gp140, respectively, could be purified by immunoaffinity chromatography. Purified UG21 gp140 from S+ and S− media possessed biological functionality as evidenced by CD4 and monoclonal antibody (Mab) binding. In contrast, UG21 gp140 from P− medium appears to be misfolded and non-functional. Despite the possession of a different N-linked glycan profile, UG21 gp140 from S− media shows very similar CD4 and Mab binding characteristics to S+ UG21 gp140. The relevance of these findings to HIV vaccine development is discussed.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6


  1. Battista PJ, Tilkins ML, Judd, DA, Godwin, GP, Gorfien SF (1994) Serum-free media for the culture of Chinese hamster ovary cells. Am Biotechnol Lab 12:64–68

  2. Biller M, Bolmstedt A, Hemming A, Olofsson S (1998) Simplified procedure for fractionation and structural characterisation of complex mixtures of N-linked glycans, released from HIV-1 gp120 and other highly glycosylated viral proteins. J Virol Methods 76:87–100

  3. Bristow RGW, Douglas AR, Skehel JJ, Daniels RS (1994) Annalysis of murine antibody responses to baculovirus-expressed human immunodeficiency virus type 1 envelope glycoproteins. J Gen Virol 75:2089–2095

  4. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, Katinger H (1994) Generation of human monoclonal antibodies against HIV-1 proteins: electrofusion and Epstein–Barr virus transformation for peripheral blood lymphocyte immortalisation. AIDS Res Hum Retroviruses 10:359–369

  5. Castle P, Robertson JS (1999) In: Brown F, Cartwright T, Horaud F, Spieser JM (eds) Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals: viral safety and regulatory aspects. Developments in biological standardization, vol 99. Karger, Basel, pp 191–196

  6. Chapman BS, Thayer RM, Vincent KA, Haigwood NI (1991) Effect of intron A from human cytomegalovirus (Towne) intermediate early gene on heterologous expression in mammalian cells. Nucleic Acids Res 19:3979–3986

  7. Cockett MI, Bebbington CR, Yarranton GT (1991) The use of engineered EIA genes to transactivate the hCMV-MIE promoter on permanent CHO cell lines. Nucleic Acids Res 19:319–325

  8. Datema R, Olofsson S, Reomero PA (1987) Inhibitors of protein glycosylation and glycoprotein processing in viral systems. Pharmacol Ther 33:221–286

  9. Feizi T, Childs RA, Kogelberg H (1994) The new biology of carbohydrates. Glycobiology 4:106–109

  10. Froud SJ (1999) The development, benefits and disadvantages of serum-free medium. In: Brown F, Cartwright T, Horaud F, Spieser JM (eds) Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals: viral safety and regulatory aspects. Developments in biological standardization, vol 99. Karger, Basel, pp 157–166

  11. Gawlitzek M, Valley U, Nimtz M, Wagner R, Conradt HS (1995) Characterization of changes in the glycosylation pattern of recombinant proteins from BHK-21 cells due to different culture conditions. J Biotechnol 42:117–131

  12. Geisse S, Gram H, Kleuser B, Kocher HP (1996) Eukaryotic expression systems: a comparison. Protein Expr Purif 8:271–282

  13. Geyer H, Holschbach C, Hunsmann G, Schneider J (1988) Carbohydrates of human immunodeficiency virus. J Biol Chem 263:11760–11767

  14. Goochee CF, Monica T (1990) Environmental effects on protein glycosylation. Bio/technology 8:421–427

  15. Griffiths JB, Racher AJ (1994) Cultural and physiological factors affecting expression of recombinant proteins. Cytotechnology 15:3–9

  16. Haldankar R, Kopchick JJ, Ridgway D (1999) Stable production of a human growth hormone antagonist from CHO cells adapted to serum-free suspension culture. Biotechnology Prog 15:336–346

  17. Hata J-I, Tamura T, Yokoshima S, Yamashita S, Kabeno S, Matsumoto K, Onodera K (1992) Chemically-defined medium for the production of biologically-active substances of CHO cells. Cytotechnology 10:9–14

  18. Jeffs SA, McKeating J, Lewis S, Craft H, Biram D, Stephens PE, Brady RL (1996) Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. J Gen Virol 77:1403–1410

  19. Jeffs SA, Jones S, Kebble B, Holmes H, Bolgiano B, Crane D Stebbings R (1999) Characterisation of oligomeric recombinant envelope glycoproteins from primary isolates of HIV-1. The fourth European conference on experimental AIDS research (ECEAR '99), Tampere, 18–21 June 1999. Monduzzi Editore International Proceedings Division, Bologna, pp 195–200

  20. Jeffs SA, Shotton C, Balfe P, McKeating JA (2002) Truncated gp120 envelope glycoprotein virus 1 elicits a broadly-reactive neutralizing immune response. J Gen Virol 83:2723–2732

  21. Jeffs SA, Goriup S, Kebble B, Crane D, Bologiano B, Sattentau Q, Jones S, Holmes H (2004) Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 22:1032–1046

  22. Kuroda K, Geyer H, Geyer R, Doerfler W, Klenk H-D (1990) The oligosaccharides of influenza haemagglutinin expressed in insect cells by a baculovirus vector. Virology 174:418–429

  23. Kuroda K, Veit M, Klenk H-D (1991) Retarded processing of influenza haemagglutinin in insect cells. Virology 180:159–165

  24. Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J (1995) Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5:813–822

  25. Mauer HR (1992) Towards serum-free, chemically-defined media for mammalian cell culture. In: Freshney RI (ed) Animal cell culture: a practical approach, 2nd edn. IRL, Oxford

  26. McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, Kayman SC, Wu Z, Pinter A, Dean C, Sodroski J, Weiss RA (1993) Characterisation of neutralising monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol 67:4932–4944

  27. Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, Feizi T (1988) Carbohydrate structures of the human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. Biochem J 254:599–603

  28. Mizuochi T, Mathews TJ, Kato M, Hansako J, Titani K, Solomon J, Feizi T (1990) Diversity of oligosaccharide structures on the envelop glycoprotein gp120 of human immunodeficiency virus type 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues. J Biol Chem 265:8519–8524

  29. Montagnier L, Clavel F, Kurst B, Chamaret S, Rey F, Barre-Sinoussi F, Chermann JC (1985) Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy associated virus. Virology 144:283–289

  30. Moore JP, McKeating JA, Jones IM, Stephens PE, Clements G, Thomson S, Weiss RA (1990) Characterisation of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and sCD4. AIDS 4:307–315

  31. Moore JP, Parren PWHI, Burton DR (2001) Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development. J Virol 75:5721–5729

  32. Morikawa Y, Moore JP, Jones IM (1990) HIV-1 envelope protein gp120 expression by secretion in E.coli: assessment of CD4 binding and use in epitope mapping. J Virol Methods 29:105–114

  33. Ozturk SS Palsson BO (1991) Physiological changes during the adaption of hybridoma cells to low serum and serum-free media. Biotechnol Bioeng 37:35–46

  34. Patel TP, Parekh RB, Moellering BJ, Prior CP (1992) Different culture methods lead to differences in glycosylation of a murine monoclonal antibody. Biochem J 285:839–845

  35. Redfield RR, Birx DL, Ketter N, Tramont E, Polonis V, Davis C, Brundage JF, Smith G, Johnson S, Fowler A, Wierzba T, Shafferman A, Volvovitz F, Oster C, Burke DS (1991) A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. New Engl J Med 324:1677–1684

  36. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 76:7293–7305

  37. Sattentau QJ, Moulard M, Brivet B, Botto F, Guillemot J-C, Mondor I, Poignard P, Ugolini S (1999) Antibody neutralisation of HIV-1 and the potential for vaccine design. Immunol Lett 66:143–149

  38. Scanlan CN, Pantophlet R, Wormald MW, Saphire EO, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR (2002) The broadly neutralising anti-human immunodeficiency virus type 1 antibody 2G12 recognises a cluster of α1→2 mannose residues on the outer face of gp120. J Virol 76:7306–7321

  39. Schutt C, Furll B, Stelter F, Jack RS, Witt S (1997) CHO transfectants produce large amounts of recombinant protein in suspension culture. J Immunol Methods 204:99–102

  40. Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege A-M, Berman P, Twaddell T, Stablein D, Sposto R, Siliciano R, Matthews TJ (1993) Induction of HIV-1 neutralisation and syncitium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 342:69–73

  41. Sinacore MS, Drapeau D, Adamson SR (2000) Adaption of mammalian cells to growth in serum-free media. Mol Biotechnol 15:249–257

  42. Silvera P, Flanagan B, Kent K, Rud E, Powell C, Corcoran C, Bruck C, Thiriart C, Haigwood NL, Stott EJ (1994) Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques. AIDS Res Hum Retroviruses 10:1295–1304

  43. Steimer KS, Haigwood NL (1991) Importance of conformation on the neutralising antibody response to HIV-1 gp120. Biotechnol Ther 2:63–89

  44. Taverna M, Tran NT, Valentin C, Level O, Merry T, Kolbe HVJ, Ferrier D (1999) A multi-mode chromatographic method for the comparison of the N-glycosylation of a recombinant HIV envelope glycoprotein (gp160s-MN/LAI) purified by two different processes. J Biotechnol 68:37–48

  45. UNAIDS (2002) AIDS epidemic update: December 2002. WHO, Geneva (UNAIDS/02.46E ISBN 92-9173-253-2)

  46. Viscidi R, Ellerbeck E, Garrison L, Midthun K, Clements ML, Clayman B, Fernie B, Smith G (1990) Characterisation of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. AIDS Res Hum Retroviruses 6:1251–1256

  47. Watson E, Shah B, Leiderman L, Hsu YR, Karkare S, Lu HS, Lin FK (1994) Comparison of N-linked oligosaccharides of human tissue kallikrein produced by Chinese hamster ovary cells on microcarrier beads and in serum-free culture. Biotechnol Prog 10:39–44

  48. Yeh J-C, Seals JR, Murphy CI, van Halbeek H, Cummings RD (1993) Site-specific N glycosylation and oligosaccharide structures of recombinant HIV-1 gp120 derived from a baculovirus expression system. Biochemistry 32:11087–11099

  49. Yuen CT, Gee CF, Jones C (2002) High-performance liquid chromatographic profiling of fluorescent labelled N-glycans in glycoproteins. Biomed Chromatogr 16:247–254

  50. Zang M, Trautmann H, Gandor C, Messi F, Asselbergs F, Leist C, Fietcher A, Reiser J (1995) Production of recombinant proteins in Chinese hamster ovary cells using protein-free cell culture medium. Biotechnology 13:389–392

  51. Zhu X, Borchers C, Bienstock RJ, Tomer KB (2000) Mass spectrometric characterisation of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39:11194–11204

Download references

Author information

Correspondence to S A. Jeffs.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jeffs, S.A., Goriup, S., Stacey, G. et al. Comparative analysis of HIV-1 recombinant envelope glycoproteins from different culture systems. Appl Microbiol Biotechnol 72, 279–290 (2006). https://doi.org/10.1007/s00253-005-0256-7

Download citation


  • Chinese Hamster Ovary
  • Simian Immunodeficiency Virus
  • T175 Flask
  • Spinner Flask
  • Cumulative Yield